# US 2021/0010085 A1 · Materials and methods for stratifying and treating cancers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0010085 A1
- Document ID: US20210010085A1
- Status: Published application
- Kind: A1
- Application number: 16/637,975
- Filed: 2018-08-10
- Published: 2021-01-14
- Earliest claimed: 2017-08-10
- Assignees: The Institute of Cancer Research: Royal Cancer Hospital; The Royal Marsden NHS Foundation Trust
- Applicants: The Institute of Cancer Research Royal Cancer Hospital; The Royal Marsden NHS Foundation Trust
- Inventors: Alex Lee; Paul Huang; Maggie Cheang; Robin Jones
- Web page: https://patentgrep.com/patent/US20210010085A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61P 35/00: Antineoplastic agents
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- G06F 18/24137: {Distances to cluster centroïds}
- G16B 25/00: ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B 40/00: ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16H 20/00: ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- C07K 2317/21: from primates, e.g. man
- C12Q 2600/106: Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C12Q 2600/158: Expression markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G06F: ELECTRIC DIGITAL DATA PROCESSING (computer systems based on specific computational models G06N)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA

## Abstract

The present invention relates to materials and methods for stratifying and treating cancers and to methods of identifying/selecting patients for treatment of cancer with tyrosine kinase inhibitors. Gene expression profiles, TP53 mutations and FGFR1 and PDGFRA expression are used to identify/select/stratify the cancers and patients.

## Claims

### Claim 1

A method of selecting an individual with cancer for treatment with a TKI, the method comprising:
(a) determining the expression levels in a biological sample obtained from the individual of 40 or more of the genes selected from table 4, wherein said biological sample comprises cells, nucleic acids and/or proteins from cancer, and
(b) selecting an individual for treatment with the TKI based on the expression levels of those genes.

### Claim 2 (depends on 1)

A method according to claim 1, wherein the expression levels of the 40 or more of the genes determined in said step (a) may be compared with:
(i) a first reference centroid corresponding to the expression profile of said 40 or more genes determined in a first group of subjects known to have cancer with PDGFRA-Hi/FGFR1-Lo expression;
(ii) a second reference centroid corresponding to the expression profile of said 40 or more genes determined in a second group of subjects known to have cancer with (a) mutant TP53 and (b) PDGFRA/FGFR1 expression that is not PDGFRA-Hi/FGFR1-Lo;
(iii) a third reference centroid corresponding to the expression profile of said 40 or more genes determined in a third group of subjects known to have cancer with (a) a gene expression profile having a closer match to the centroid of subgroup A shown in table 3 than subgroups B or C, and (b) TP53 wildtype, and (c) PDGFRA/FGFR1 expression that is not PDGFRA-Hi/FGFR1-Lo;
(iv) a fourth reference centroid corresponding to the expression profile of said 40 or more genes determined in a fourth group of subjects known to have cancer with (a a gene expression profile having a closer match to the centroid of subgroup B shown in table 3 than subgroups A or C, and (b) TP53 wildtype, and (c) PDGFRA/FGFR1 expression that is not PDGFRA-Hi/FGFR1-Lo; and
(v) a fifth reference centroid corresponding to the expression profile of said 40 or more genes determined in a fifth group of subjects known to have cancer with (a) a gene expression profile having a closer match to the centroid of subgroup C shown in table 3 than subgroups A or B, and (b) TP53 wildtype, and (c) PDGFRA/FGFR1 expression that is not PDGFRA-Hi/FGFR1-Lo;
wherein the individual is selected for treatment with the TKI in step (b) when the expression levels determined in said step (a) of the 40 or more genes are a closer match to said third reference centroid than said first, second, fourth or fifth reference centroids.

### Claim 3 (depends on 2)

The method of claim 2, wherein the PDGFRA/FGFR1 expression is PDGFRA-Hi/FGFR1-Hi or PDGFRA-Lo/FGFR1-Lo or PDGFRA-Lo/FGFR1-Hi.

### Claim 4 (depends on 1)

The method of claim 1, wherein step (b) comprises selecting the individual for treatment with a TKI if the expression levels of the 40 or more of the genes determined in said step (a) are a closer match to the reference centroid A(3) shown in table 6, than any of reference centroids IHC+(1), TP53(2), B(4), C(5)) shown in table 6.

### Claim 5 (depends on 1)

The method according to claim 1 wherein the expression levels of at least 40, at least 45, at least 50, at least 6, at least 70, at least 80, at least 90, at least 100, at least 110, at least 120, at least 130, at least 240, at least 150, at least 160, at least 170, at least 180, at least 190, at least 200, at least 210, at least 220 or all 225 of the genes in table 4 are determined.

### Claim 6 (depends on 1)

The method according to claim 1 wherein the expression levels determined in step (a) are the nucleic acid expression levels.

### Claim 7 (depends on 6)

The method according to claim 6, wherein the expression levels are determined using an RNA microarray, Nanostring technology, RNA-Seq or quantitative PCR.

### Claim at position 8

8-33. (canceled)

### Claim 34 (depends on 1)

The method according to claim 1 further comprising the step of obtaining the sample of cancer cells, nucleic acids and/or proteins from the individual, wherein the biological sample is obtained from tissue, cells or fluid from the individual.

### Claim 35

(canceled)

### Claim 36

(canceled)

### Claim 37 (depends on 1)

A method of treating cancer with a tyrosine kinase inhibitor (TKI) in an individual in need thereof, wherein the individual has been selected for treatment according to claim 1.

### Claim 38

(canceled)

### Claim 39

(canceled)

### Claim 40

(canceled)

### Claim 41 (depends on 37)

The method according to claim 37 wherein the cancer is selected from: soft tissues sarcoma (STS), metastatic renal cell carcinomas (mRCC), gastrointestinal stromal tumour (GIST), hepatocellular carcinoma (HCC), neuroendocrine tumour (NET), medullary thyroid cancer (MTC), non-squamous non-small cell lung cancer (non-squamous NSCLC), and chronic myeloid leukaemia (CML).

### Claim 42 (depends on 41)

The method according to claim 41, wherein the cancer is STS or advanced STS.

### Claim 43

(canceled)

### Claim 44 (depends on 37)

The method according to claim 37 wherein the TKI is selected from: Pazopanib, Regorafenib, Sorafenib, Sunitinib, Lenvatinib, Axitinib, Nintedanib, and Ponatinib, and pharmaceutically acceptable salts thereof.

### Claim 45 (depends on 44)

The method according to claim 44 wherein the TKI is Pazopanib.

### Claim 46 (depends on 37)

The method according to claim 37 wherein the TKI is Pazopanib and the cancer is soft tissue sarcoma or advanced soft tissue sarcoma.

### Claim 47

(canceled)

### Claim 48

A kit for use in identifying a cancer suitable for treatment with a TKI, the kit comprising probes for detecting the expression levels of at least 40 at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 110, at least 120, at least 130, at least 240, at least 150, at least 160, at least 170, at least 180, at least 190, at least 200, at least 210, at least 220 or all 225 of the genes in table 4.

### Claim at position 24

49-53. (canceled)

### Claim 54

A method of determining a prognosis following TKI treatment in an individual, the method comprising determining the expression levels of 40 or more genes from table 4.

### Claim 55 (depends on 54)

The method according to claim 54 wherein the individual is determined to have a good prognosis following TKI treatment if they have a cancer having the expression levels of the 40 or more genes in table 4 a closer match to a third reference centroid than said first, second, fourth or fifth reference centroids, wherein the reference centroids are:
(a) a first reference centroid corresponding to the expression profile of said 40 or more genes determined in a first group of subjects known to have cancer with PDGFRA-Hi/FGFR1-Lo expression;
(b) a second reference centroid corresponding to the expression profile of said 40 or more genes determined in a second group of subjects known to have cancer with mutated TP53 and PDGFRA/FGFR1 expression that is not PDGFRA-Hi/FGFR1-Lo expression;
(c) a third reference centroid corresponding to the expression profile of said 40 or more genes determined in a third group of subjects known to have cancer with (a) a gene expression profile having a closer match to the centroid of subgroup A shown in table 3 than subgroups B or C, and (b) TP53 wild-type, and (c) PDGFRA/FGFR1 expression that is not PDGFRA-Hi/FGFR1-Lo expression;
(d) a fourth reference centroid corresponding to the expression profile of said 40 or more genes determined in a fourth group of subjects known to have cancer with (a) a gene expression profile having a closer match to the centroid of subgroup B shown in table 3 than subgroups A or C, and (b) TP53 wild-type, and (c) PDGFRA/FGFR1 expression that is not PDGFRA-Hi/FGFR1-Lo expression; and
(e) a fifth reference centroid corresponding to the expression profile of said 40 or more genes determined in a fifth group of subjects known to have cancer with (a) a gene expression profile having a closer match to the centroid of subgroup C shown in table 3 than subgroups A or B, and (b) TP53 wild-type, and (c) PDGFRA/FGFR1 expression that is not PDGFRA-Hi/FGFR1-Lo expression.

### Claim 56 (depends on 54)

The method according to claim 54 wherein the individual is determined to have a poor prognosis if they have a cancer having the expression levels of the 40 or more genes in table 4 a closer match to a first, second, fourth or fifth reference centroid than a third reference centroids, wherein the reference centroids are:
(a) a first reference centroid corresponding to the expression profile of said 40 or more genes determined in a first group of subjects known to have cancer with PDGFRA-Hi/FGFR1-Lo expression;
(b) a second reference centroid corresponding to the expression profile of said 40 or more genes determined in a second group of subjects known to have cancer with mutated TP53 and PDGFRA/FGFR1 expression that is not PDGFRA-Hi/FGFR1-Lo expression;
(c) a third reference centroid corresponding to the expression profile of said 40 or more genes determined in a third group of subjects known to have cancer with (a) a gene expression profile having a closer match to the centroid of subgroup A shown in table 3 than subgroups B or C, and (b) TP53 wild-type, and (c) PDGFRA/FGFR1 expression that is not PDGFRA-Hi/FGFR1-Lo expression;
(d) a fourth reference centroid corresponding to the expression profile of said 40 or more genes determined in a fourth group of subjects known to have cancer with (a) a gene expression profile having a closer match to the centroid of subgroup B shown in table 3 than subgroups A or C, and (b) TP53 wild-type, and (c) PDGFRA/FGFR1 expression that is not PDGFRA-Hi/FGFR1-Lo expression; and
(e) a fifth reference centroid corresponding to the expression profile of said 40 or more genes determined in a fifth group of subjects known to have cancer with (a) a gene expression profile having a closer match to the centroid of subgroup C shown in table 3 than subgroups A or B, and (b) TP53 wild-type, and (c) PDGFRA/FGFR1 expression that is not PDGFRA-Hi/FGFR1-Lo expression.

### Claim at position 28

57-63. (canceled)

### Claim 64

A method of treating cancer in an individual identified as having a cancer having the expression levels of the 40 or more genes in table 4 a closer match to a first, second, fourth or fifth reference centroid than a third reference centroids, the method comprising administering an anti-PDGFRA antibody, binding fragment thereof or a pharmaceutical composition comprising said antibody or said binding fragment to the individual, wherein the reference centroids are:
(a) a first reference centroid corresponding to the expression profile of said 40 or more genes determined in a first group of subjects known to have cancer with PDGFRA-Hi/FGFR1-Lo expression;
(b) a second reference centroid corresponding to the expression profile of said 40 or more genes determined in a second group of subjects known to have cancer with mutated TP53 and PDGFRA/FGFR1 expression that is not PDGFRA-Hi/FGFR1-Lo expression;
(c) a third reference centroid corresponding to the expression profile of said 40 or more genes determined in a third group of subjects known to have cancer with (a) a gene expression profile having a closer match to the centroid of subgroup A shown in table 3 than subgroups B or C, and (b) TP53 wild-type, and (c) PDGFRA/FGFR1 expression that is not PDGFRA-Hi/FGFR1-Lo expression;
(d) a fourth reference centroid corresponding to the expression profile of said 40 or more genes determined in a fourth group of subjects known to have cancer with (a) a gene expression profile having a closer match to the centroid of subgroup B shown in table 3 than subgroups A or C, and (b) TP53 wild-type, and (c) PDGFRA/FGFR1 expression that is not PDGFRA-Hi/FGFR1-Lo expression; and
(e) a fifth reference centroid corresponding to the expression profile of said 40 or more genes determined in a fifth group of subjects known to have cancer with (a) a gene expression profile having a closer match to the centroid of subgroup C shown in table 3 than subgroups A or B, and (b) TP53 wild-type, and (c) PDGFRA/FGFR1 expression that is not PDGFRA-Hi/FGFR1-Lo expression.

### Claim 65 (depends on 1, 64)

The method according to claim 64, wherein the anti-PDGFRA antibody, binding fragment or composition is for use in a method comprising:
(i) performing the method of claim 1 on at least one sample obtained from the individual, wherein the individual is identified as having a cancer having the expression levels of the 40 or more genes in table 4 a closer match to a first, second, fourth or fifth reference centroid than a third reference centroids, wherein the reference centroids are:
(a) a first reference centroid corresponding to the expression profile of said 40 or more genes determined in a first group of subjects known to have cancer with PDGFRA-Hi/FGFR1-Lo expression;
(b) a second reference centroid corresponding to the expression profile of said 40 or more genes determined in a second group of subjects known to have cancer with mutated TP53 and PDGFRA/FGFR1 expression that is not PDGFRA-Hi/FGFR1-Lo expression;
(c) a third reference centroid corresponding to the expression profile of said 40 or more genes determined in a third group of subjects known to have cancer with (a) a gene expression profile having a closer match to the centroid of subgroup A shown in table 3 than subgroups B or C, and (b) TP53 wild-type, and (c) PDGFRA/FGFR1 expression that is not PDGFRA-Hi/FGFR1-Lo expression;
(d) a fourth reference centroid corresponding to the expression profile of said 40 or more genes determined in a fourth group of subjects known to have cancer with (a) a gene expression profile having a closer match to the centroid of subgroup B shown in table 3 than subgroups A or C, and (b) TP53 wild-type, and (c) PDGFRA/FGFR1 expression that is not PDGFRA-Hi/FGFR1-Lo expression; and
(e) a fifth reference centroid corresponding to the expression profile of said 40 or more genes determined in a fifth group of subjects known to have cancer with (a) a gene expression profile having a closer match to the centroid of subgroup C shown in table 3 than subgroups A or B, and (b) TP53 wild-type, and (c) PDGFRA/FGFR1 expression that is not PDGFRA-Hi/FGFR1-Lo expression; and
(ii) administering a therapeutically effective amount of said anti-PDGFRA antibody, said binding fragment thereof or said pharmaceutical composition.

### Claim at position 31

66-69. (canceled)

### Claim 70 (depends on 64)

The method of claim 64, wherein the antibody comprises olaratumab.
